QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.

Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.

Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma,  modelling experts, and experienced project managers.

Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.

Press

7Dec 2012

Retrospective study in Osteoporosis International

Oskar Ström published a retrospective study in Osteoporosis International analyzing the impact of automatic generic substitution on treatment persistence in 36,433 patients. Between 2006 and 2009, the proportion of prescriptions constituting a generic substitution increased from 10.8% to 45.2%, and the proportion of patients persisting with alendronate treatment for 12 months fell from 66.9% to 51.7%. No difference was observed in persistence with proprietary risedronate during the same period. […]